68
Participants
Start Date
February 14, 2023
Primary Completion Date
April 1, 2028
Study Completion Date
October 15, 2028
VO659
VO659 is an antisense oligonucleotide targeting CAG repeats in mRNA transcripts
RECRUITING
Rigshospitalet, Copenhagen
RECRUITING
Centre Hospitalier Universitaire dÁngers, Angers
RECRUITING
CHU Gui de Chauliac Montpellier- Expert Center of Neurogenetic diseases, Department of Neurology, Montpellier
RECRUITING
Universtiry Hospitals Pitie Salpetriere - Charles foix - Paris, Paris
RECRUITING
Katholisches Klinikum Bochum, Bochum
RECRUITING
Deutsches Zentrum fur Neurodegenerative Erkrankungen (DZNE), Bonn
RECRUITING
Universitatsklinikum Essen - Neurologie, Essen
RECRUITING
Universitatsklinikum Tübingen, Tübingen
RECRUITING
Meir Medical Center, Kfar Saba
RECRUITING
Sourmansky Medical Center, Tel Aviv
RECRUITING
Leiden University Medical Center LUMC, Leiden
RECRUITING
Radbout University Medical Centre, Nijmegen
RECRUITING
University College London Hospitals NHS Foundation, London
RECRUITING
John Radcliffe Hospital, Oxford
Vico Therapeutics B. V.
INDUSTRY